Molecular Partners Ag (MOLN) Profit After Tax (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Profit After Tax of -$16784.9 for Q1 2026, up 10.02% year-over-year from -$15256.6 in Q1 2025, and up 99.98% quarter-over-quarter from -$77.1 million in Q4 2025.
Molecular Partners Ag (MOLN) Profit After Tax (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Profit After Tax for 7 consecutive years, with -$16784.9 the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax rose 10.02% year-over-year to -$16784.9; the TTM figure through Mar 2026 stood at -$77.2 million (down 214.24% YoY), while the FY2025 annual figure was -$77.2 million, down 214.23% from the prior year.
- Profit After Tax climbed to -$16784.9 in Q1 2026 per MOLN's latest filing, from -$77.1 million in the prior quarter.
- Across five years, Profit After Tax topped out at $122.2 million in Q4 2022 and bottomed at -$77.1 million in Q4 2025.
- Historically, Profit After Tax has averaged $1.2 million across 5 years, with a median of -$16677.6 in 2024.
- Annual changes were most pronounced in 2022 — Profit After Tax soared 1020.39% — and 2023, when it sank 278.7%.
- Molecular Partners Ag's Profit After Tax stood at $122.2 million in 2022, then plunged by 157.15% to -$69.8 million in 2023, then jumped by 196.84% to $67.6 million in 2024, then tumbled by 214.06% to -$77.1 million in 2025, then soared by 99.98% to -$16784.9 in 2026.
- Business Quant data shows MOLN's Profit After Tax at -$16784.9 in Q1 2026, -$77.1 million in Q4 2025, and -$15258.8 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | -16,784.95 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16,784.95 |
| Dec 31, 2025 | -77.14 Mn |
| Sep 30, 2025 | -15,258.84 |
| Jun 30, 2025 | -27,182.36 |
| Mar 31, 2025 | -18,653.55 |
| Dec 31, 2024 | 67.63 Mn |
| Sep 30, 2024 | -20,607.22 |
| Jun 30, 2024 | -16,677.58 |
| Mar 31, 2024 | -12,974.85 |
| Dec 31, 2023 | -69.83 Mn |
| Sep 30, 2023 | -12,950.69 |
| Jun 30, 2023 | -17.78 Mn |
| Mar 31, 2023 | -15,977.42 |
| Dec 31, 2022 | 122.19 Mn |
| Sep 30, 2022 | -15,424.16 |
| Jun 30, 2022 | -4.70 Mn |
| Mar 31, 2022 | 168,520.72 |
| Dec 31, 2021 | -69.13 Mn |
| Sep 30, 2021 | -13,406.09 |
| Jun 30, 2021 | -36.79 Mn |